REGN U.S.: Nasdaq


    After Hours
    Last Updated: Sep 9, 2022 7:56 p.m. EDT Delayed quote

    $ 724.30

    -0.02 0.00%
    After Hours Volume: 16.65K
    Close Chg Chg %
    $724.32 15.47 2.18%
    Advanced Charting
    Volume: 2.14M 65 Day Avg: 673.53K
    318% vs Avg
    707.25 Day Range 754.67
    538.01 52 Week Range 754.67

    Your Watchlists

    Customize 江湖电竞最新版比赛(江湖电竞投注app网站)

    Have Watchlists? Log in to see them here or sign up to get started.

    Chg/Chg %
    No Items in Watchlist

    There are currently no items in this Watchlist.

    No Saved Watchlists

    Create a list of the investments you want to track.

    Uh oh

    Something went wrong while loading Watchlist.

    Recently Viewed Tickers

    No Recent Tickers

    Visit a quote page and your recently viewed tickers will be displayed here.

    REGN Overview

    Key Data

    • Open $711.73
    • Day Range 707.25 - 754.67
    • 52 Week Range 538.01 - 754.67
    • Market Cap $77.27B
    • Shares Outstanding 107.19M
    • Public Float 102.55M
    • Beta 0.67
    • Rev. per Employee $1.372M
    • P/E Ratio 14.46
    • EPS $50.10
    • Yield N/A
    • Dividend N/A
    • Ex-Dividend Date N/A
    • Short Interest 2.93M 08/15/22
    • % of Float Shorted 2.86%
    • Average Volume 673.53K


    5 Day
    • 24.75%
    1 Month
    • 15.21%
    3 Month
    • 26.67%
    • 14.69%
    1 Year
    • 11.35%

    Analyst Ratings

    • Sell
    • Under
    • Hold
    • Over
    • Buy
    Number of Ratings 25 Full Ratings

    Recent News

    Read full story

    Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day

    Read full story

    Regeneron Gets Praised by Wall Street. High-Dose Eylea Data Look ‘Strong.’

    Regeneron stock price target raised to $790 from $718 at Truist

    Read full story

    Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day

    Read full story

    Regeneron Stock Surges on Promising Eye Disease Drug Trial Results

    Regeneron Shares Soar on Positive Trial News

    Regeneron stock price target raised to $760 from $635 at Evercore ISI

    Regeneron Says Retinal Treatment Trials Met Primary Endpoints

    Regeneron says Eylea met the primary endpoints in two trials

    Regeneron Pharmaceuticals Inc. said Thursday that an 8-milligram dose of aflibercept successfully treated patients with diabetic macular edema and wet age-related macular degeneration in a pair of pivotal trials. Regenero...

    Regeneron stock to resume trading at 9:50 a.m. ET

    Regeneron aflibercept 8 diabetic macular edema treatment meets primary endpoints in 2 trials

    Regeneron's stock was little changed premarket prior to trading halt

    Regeneron stock halted for news pending

    Read full story

    Regeneron Pharmaceuticals Inc. stock rises Wednesday, outperforms market

    Read full story

    Regeneron Pharmaceuticals Inc. stock falls Tuesday, underperforms market

    Regeneron tops earnings expectations amid 'record' sales of several products

    Regeneron Pharmaceuticals Inc. topped expectations with its second-quarter financial results Wednesday morning, though revenue and profits both fell from a year earlier. The company logged net income of $852 million, or $...

    Regeneron Q2 revenue $2.86 bln vs. $5.14 bln a year ago; FactSet consensus $2.79 bln

    Regeneron Q2 adj. EPS $9.77; FactSet consensus $8.62

    Regeneron Q2 EPS $7.47 vs. $27.97 a year ago

    Regeneron: FDA to Review Extended Eylea Regimen in Diabetic Retinopathy >REGN

    9 Analysts Have This to Say About Regeneron Pharmaceuticals

    on Benzinga.com

    Analyst Ratings for Regeneron Pharmaceuticals

    on Benzinga.com

    Jefferies Upgrades Regeneron Pharmaceuticals: Here's What You Need To Know

    on Benzinga.com

    'Highly Compelling' Eye Drug Data Has Wall Street Stampeding To Buy This 'Large Cap Growth Story.' Even After $15B In Market Cap Was Added

    on Benzinga.com

    Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022

    on Benzinga.com

    Company News for Sep 9, 2022

    Companies in The News Are: REGN, JPM, CASY, GME

    on Zacks.com

    What 9 Analyst Ratings Have To Say About Regeneron Pharmaceuticals

    on Benzinga.com

    Regeneron (REGN) Up on Higher Dose Eye Drug Studies Success

    Regeneron (REGN) stock jumps as aflibercept 8 mg with 12- and 16-week dosing regimens in patients with DME and wAMD meet primary goals.

    on Zacks.com

    SVB Securities Reaffirms Their Hold Rating on Regeneron (REGN)

    SVB Securities analyst David Risinger maintained a Hold rating on Regeneron (REGN - Research Report) today and set a price target of $756.00. The company's shares closed yesterday at $708.85.Risinger covers the Healthcare ...

    on TipRanks.com

    TipRanks Friday PreMarket Update! DMS Soars on Buyout Bid, DOCU & ZS Raise Forecasts, + More!

    Today's Daily Stock Market Preview – Friday September 9th 2022 Watch the TipRanks premarket news and stay up to date on stock market news before the market opens. We touch on earnings reports, the biggest gainers & los...

    on TipRanks.com

    Regeneron Pharmaceuticals To $851? Here Are 5 Other Price Target Changes For Friday

    on Benzinga.com

    US Stock Futures Surge; Fed Speakers In Focus

    on Benzinga.com

    Why ShiftPixy Surged Around 177%; Here Are 71 Biggest Movers From Yesterday

    on Benzinga.com

    Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary

    on Benzinga.com

    Why Regeneron Pharmaceuticals Stock Is Crushing It Today

    on Motley Fool

    Regeneron-Sanofi Eczema Drug Shows Improvements In Itchy Inflammatory Skin Disease

    on Benzinga.com

    SpringWorks (SWTX), GSK Expand Deal to Treat Multiple Myeloma

    Per the partnership, SpringWorks Therapeutics (SWTX) will supply nirogacestat to GSK's (GSK) development program for its multiple myeloma drug, Blenrep.

    on Zacks.com

    Regeneron (NASDAQ:REGN) Jumps on Achieving Primary Endpoints in DME & wAMD

    Regeneron shares (NASDAQ:REGN) surged today after its Aflibercept met primary endpoints in two global trials for diabetic macular edema (DME) and wet age-related macular degeneration (wAMD). Importantly, a major part of th...

    on TipRanks.com

    Why Bilibili Is Trading Lower By Over Around 14%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session

    on Benzinga.com

    AeroVironment, Snap And Some Other Big Stocks Moving Higher On Thursday

    on Benzinga.com

    Regeneron Pharmaceuticals Inc.

    Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.


    Name Chg % Market Cap
    Amgen Inc. 1.10% $131.3B
    Moderna Inc. 0.35% $55.27B
    Gilead Sciences Inc. 0.56% $81.59B
    BioNTech SE ADR 2.49% $35.72B
    Illumina Inc. 0.40% $32.61B
    Samsung Biologics Co. Ltd. -0.12% ₩57.65T
    Biogen Inc. 2.12% $30.18B
    Seagen Inc. 1.84% $28.15B
    Novozymes A/S Series B 2.41% kr.113.22B